Company
Bausch Lomb
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
27
510(k), De Novo and PMA
Device trials
98
As lead sponsor, any status
Adverse event reports
334
Received Nov 1, 2025 to Nov 20, 2026
Recall records
141
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
BLCO
NYSE · Bausch & Lomb Corp
Public float
$557M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$5.10B
Fiscal year ending Dec 31, 2025
Net income
-$360M
Fiscal year ending Dec 31, 2025
R&D spending
$371M
Fiscal year ending Dec 31, 2025
Cash
$513M
As of Sep 30, 2026
Long-term debt
$5.02B
As of Sep 30, 2026
Shares outstanding
357.5M
As of Oct 21, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $3.36B | – |
| 2024 | – | – | $631M | – |
| 2023 | – | – | $2.28B | – |
| 2022 | – | – | $2.44B | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
No 5%+ shareholder filings, SBIR grants or venture investors found under the name Bausch Lomb.
Latest FDA decisions
The 8 newest of 27 since 2015.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
26 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06997003 · 81 participants (planned) · Start Jun 16, 2025 · Primary completion May 2027
Device: Anterior treatment mode; Anterior treatment mode and 1 more · For: Hyperopia and Myopia
Sites: Zlín, Czechia
97 more trials with a free account
Reports received
334
Received Nov 1, 2025 to Nov 20, 2026. Includes 2 of another or unstated type.
Malfunction reports
80
24% of reports
Injury reports
252
75% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 18 | 18 | 0 | 0 |
| Jan 24 | 8 | 15 | 0 | 0 |
| Feb 24 | 20 | 55 | 0 | 0 |
| Mar 24 | 17 | 10 | 0 | 0 |
| Apr 24 | 10 | 22 | 0 | 0 |
| May 24 | 14 | 12 | 0 | 0 |
| Jun 24 | 4 | 12 | 0 | 0 |
| Jul 24 | 9 | 17 | 0 | 0 |
| Aug 24 | 7 | 25 | 0 | 0 |
| Sep 24 | 7 | 11 | 0 | 0 |
| Oct 24 | 13 | 19 | 0 | 0 |
| Nov 24 | 16 | 10 | 0 | 0 |
| Dec 24 | 15 | 18 | 0 | 0 |
| Jan 25 | 7 | 9 | 0 | 0 |
| Feb 25 | 5 | 19 | 0 | 1 |
| Mar 25 | 5 | 20 | 0 | 0 |
| Apr 25 | 22 | 84 | 0 | 0 |
| May 25 | 11 | 17 | 0 | 1 |
| Jun 25 | 8 | 24 | 0 | 0 |
| Jul 25 | 8 | 20 | 0 | 0 |
| Aug 25 | 5 | 24 | 0 | 0 |
| Sep 25 | 4 | 12 | 0 | 0 |
| Oct 25 | 5 | 17 | 0 | 0 |
| Nov 25 | 7 | 17 | 0 | 0 |
| Dec 25 | 7 | 27 | 0 | 0 |
| Jan 26 | 13 | 8 | 0 | 1 |
| Feb 26 | 8 | 9 | 0 | 0 |
| Mar 26 | 6 | 18 | 0 | 0 |
| Apr 26 | 8 | 25 | 0 | 1 |
| May 26 | 3 | 22 | 0 | 0 |
| Jun 26 | 2 | 33 | 0 | 0 |
| Jul 26 | 8 | 27 | 0 | 0 |
| Aug 26 | 5 | 19 | 0 | 0 |
| Sep 26 | 7 | 27 | 0 | 0 |
| Oct 26 | 6 | 20 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Akreos, SKU: AO60P0300. Akreos intraocular lensesOpen, Classified
Z-2451-2025 · Started Jun 6, 2025 · Posted by FDA Aug 26, 2025
Reason given: An off-power error was identified, which resulted in a diopter of 16, rather than the intended 3 diopter. Implantation of affected intraocular lens could result in functional visual impairment or reduction in visual acuity which could result in the need for optical or surgical correction.
Cause as FDA categorized it: Process control · Device type: Intraocular Lens (HQL)
140 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.